-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-511346-39-00
3
2025-03-28
Immune-mediated necrotizing myopathy
-
2024-513018-36-00
5
2025-03-06
Lung Diseases, Interstitial
-
2024-515451-38-00
5
2025-02-27
Primary Immune thrombocytopenia (ITP)
-
2024-514972-42-00
5
2025-02-25
Thyroid eye disease
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2023-507746-83-00
5
2024-11-27
Generalized Myasthenia Gravis
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2023-504358-36-00
5
2024-10-17
multiple sclerosis
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-509566-38-00
9
2024-08-05
gastroesophageal junction adenocarcinoma
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-508099-12-00
5
2024-06-20
Dermatitis atopic
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2023-504026-19-01
5
2024-06-05
Prostate Cancer
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501478-21-00
5
2024-03-15
Atopic Dermatitis
Eczema
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2023-505604-32-00
5
2024-01-24
Non small cell lung cancer (NSCLC)
-
2022-502660-20-00
5
2024-01-23
Follicular lymphoma